CN101087606B - 雌激素受体调节剂 - Google Patents
雌激素受体调节剂 Download PDFInfo
- Publication number
- CN101087606B CN101087606B CN2005800422962A CN200580042296A CN101087606B CN 101087606 B CN101087606 B CN 101087606B CN 2005800422962 A CN2005800422962 A CN 2005800422962A CN 200580042296 A CN200580042296 A CN 200580042296A CN 101087606 B CN101087606 B CN 101087606B
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- group
- ketone
- tetrahydrochysene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63478504P | 2004-12-09 | 2004-12-09 | |
US60/634,785 | 2004-12-09 | ||
PCT/US2005/043859 WO2006062876A2 (en) | 2004-12-09 | 2005-12-05 | Estrogen receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101087606A CN101087606A (zh) | 2007-12-12 |
CN101087606B true CN101087606B (zh) | 2010-12-29 |
Family
ID=36578441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005800422962A Expired - Fee Related CN101087606B (zh) | 2004-12-09 | 2005-12-05 | 雌激素受体调节剂 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7511152B2 (pt-PT) |
EP (1) | EP1827421B1 (pt-PT) |
JP (2) | JP2008523065A (pt-PT) |
KR (1) | KR20070085874A (pt-PT) |
CN (1) | CN101087606B (pt-PT) |
AU (1) | AU2005314230B2 (pt-PT) |
BR (1) | BRPI0518874A2 (pt-PT) |
CA (1) | CA2590860C (pt-PT) |
IL (1) | IL183543A (pt-PT) |
MX (1) | MX2007006878A (pt-PT) |
NO (1) | NO20073511L (pt-PT) |
NZ (1) | NZ555316A (pt-PT) |
RU (1) | RU2394820C2 (pt-PT) |
WO (1) | WO2006062876A2 (pt-PT) |
ZA (1) | ZA200704223B (pt-PT) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005316824B2 (en) * | 2004-12-17 | 2012-05-31 | Bionovo, Inc. | Method of using extracts of epimedium species |
US7482029B2 (en) * | 2005-04-01 | 2009-01-27 | Bionovo, Inc. | Composition for treatment of menopause |
ATE517871T1 (de) * | 2005-10-05 | 2011-08-15 | Merck Sharp & Dohme | Östrogenrezeptormodulatoren |
US7700136B2 (en) * | 2005-11-14 | 2010-04-20 | Bionovo, Inc. | Scutellaria barbata extract for the treatment of cancer |
EP2647376A1 (en) | 2007-01-22 | 2013-10-09 | Gtx, Inc. | Nuclear receptor binding agents |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
US20090042818A1 (en) * | 2007-06-22 | 2009-02-12 | Bionovo, Inc. | Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists |
US20080319051A1 (en) * | 2007-06-22 | 2008-12-25 | Bionovo, Inc. | Liquiritigenin and derivatives as selective estrogen receptor beta agonists |
AU2008285325A1 (en) * | 2007-08-08 | 2009-02-12 | Bionovo, Inc. | Extracts of Ligustrum lucidum and uses thereof |
AU2008296176A1 (en) * | 2007-09-07 | 2009-03-12 | Bionovo, Inc. | Estrogenic extracts of Asparagus conchinchinensis (Lour.) Merr of the Liliaceae Family and uses thereof |
US9155770B2 (en) * | 2007-09-07 | 2015-10-13 | Bionovo, Inc. | Estrogenic extracts of Scuttelaria barbata D. don of the labiatae family and uses thereof |
AU2008296076A1 (en) * | 2007-09-07 | 2009-03-12 | Bionovo, Inc. | Estrogenic extracts of Pueraria lobata Willd, Ohwi of the Leguminosae family and uses thereof |
JP2010539085A (ja) * | 2007-09-07 | 2010-12-16 | バイオノボ・インコーポレーテッド | マメ科ファミリーのキバナオウギのエストロゲン性抽出物およびその使用 |
WO2009067553A1 (en) * | 2007-11-19 | 2009-05-28 | Bionovo, Inc. | Anti-cancer therapy with an extract of scutellaria barbata |
WO2009070478A2 (en) * | 2007-11-19 | 2009-06-04 | Bionovo, Inc. | A process of making purified extract of scutellaria barbata d. don |
AU2008326426A1 (en) | 2007-11-19 | 2009-05-28 | Bionovo, Inc. | Methods of detecting and treatment of cancers using scuttelaria barbata extract |
WO2009067555A1 (en) * | 2007-11-19 | 2009-05-28 | Bionovo, Inc. | Scutellaria barbata extract and combinations for the treatment of cancer |
AU2009236339A1 (en) * | 2008-04-14 | 2009-10-22 | Bionovo, Inc. | Calycosin and analogs thereof for the treatment of estrogen receptor beta-mediated diseases |
JP2011519947A (ja) * | 2008-05-06 | 2011-07-14 | バイオノボ・インコーポレーテッド | 膣および外陰の委縮を治療するために使用するエストロゲン様抽出物 |
CA2726982A1 (en) * | 2008-06-05 | 2009-12-10 | Bionovo, Inc. | Method of quantification of multiple bioactives from botanical compositions |
WO2009148620A2 (en) * | 2008-06-06 | 2009-12-10 | Bionovo, Inc. | Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions |
CA2734523A1 (en) * | 2008-09-03 | 2010-03-11 | Bionovo, Inc. | Methods and compositions for the treatment of cancer |
US20100303936A1 (en) * | 2009-04-28 | 2010-12-02 | Bionovo, Inc. A Delaware Corporation | Method of reducing fat accumulation and inducing weight loss |
CA2932224A1 (en) | 2013-12-05 | 2015-06-11 | Karo Pharma Ab | Estrogen receptor beta agonists for use in treating mesothelioma |
EP3395809A4 (en) * | 2015-12-22 | 2019-06-19 | Jiangsu Hengrui Medicine Co. Ltd. | BENZOPIPERIDIN DERIVATIVE, PRODUCTION METHOD AND MEDICAL USE THEREOF |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4294926A (en) | 1979-06-15 | 1981-10-13 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4319039A (en) | 1979-06-15 | 1982-03-09 | Merck & Co., Inc. | Preparation of ammonium salt of hypocholesteremic fermentation product |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
JPS5889191A (ja) | 1981-11-20 | 1983-05-27 | Sankyo Co Ltd | 3−ヒドロキシ−ml−236b誘導体の製造法 |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
WO1984002131A1 (en) * | 1982-11-22 | 1984-06-07 | Sandoz Ag | Analogs of mevalolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals |
US4911165A (en) | 1983-01-12 | 1990-03-27 | Ethicon, Inc. | Pliabilized polypropylene surgical filaments |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4782084A (en) | 1987-06-29 | 1988-11-01 | Merck & Co., Inc. | HMG-COA reductase inhibitors |
US4885314A (en) | 1987-06-29 | 1989-12-05 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
US4820850A (en) | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
US5180589A (en) | 1988-03-31 | 1993-01-19 | E. R. Squibb & Sons, Inc. | Pravastatin pharmaceuatical compositions having good stability |
US5030447A (en) | 1988-03-31 | 1991-07-09 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions having good stability |
US4916239A (en) | 1988-07-19 | 1990-04-10 | Merck & Co., Inc. | Process for the lactonization of mevinic acids and analogs thereof |
US5118853A (en) | 1988-10-13 | 1992-06-02 | Sandoz Ltd. | Processes for the synthesis of 3-disubstituted aminoacroleins |
US5290946A (en) | 1988-10-13 | 1994-03-01 | Sandoz Ltd. | Processes for the synthesis of 3-(substituted indolyl-2-yl)propenaldehydes |
US4929437A (en) | 1989-02-02 | 1990-05-29 | Merck & Co., Inc. | Coenzyme Q10 with HMG-CoA reductase inhibitors |
US5189164A (en) | 1989-05-22 | 1993-02-23 | Sandoz Ltd. | Processes for the synthesis of syn-(E)-3,5-dihydroxy-7-substituted hept-6-enoic and heptanoic acids and derivatives and intermediates thereof |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
DE19523446A1 (de) | 1995-06-28 | 1997-01-02 | Bayer Ag | Benzotriazole |
EE200100487A (et) | 1999-03-15 | 2003-02-17 | Axys Pharmaceuticals, Inc. | Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena |
US6525036B2 (en) | 2000-01-06 | 2003-02-25 | Merck & Co., Inc. | Compounds and compositions as protease inhibitors |
AU784200B2 (en) * | 2000-02-14 | 2006-02-23 | Merck Sharp & Dohme Corp. | Estrogen receptor modulators |
GB0012209D0 (en) | 2000-05-19 | 2000-07-12 | Novartis Ag | Organic compounds |
ES2394211T3 (es) | 2000-06-20 | 2013-01-23 | Novartis Ag | Procedimiento de administración de bifosfonatos |
AU2002226965B2 (en) * | 2000-11-27 | 2006-05-18 | Merck Sharp & Dohme Corp. | Estrogen receptor modulators |
WO2003015761A1 (en) * | 2001-08-13 | 2003-02-27 | Merck & Co., Inc. | Selective estrogen receptor modulators |
CA2497934A1 (en) | 2002-09-19 | 2004-04-01 | Merck & Co., Inc. | Tryptophan hydroxylase assay |
AR051597A1 (es) | 2004-11-01 | 2007-01-24 | Merck & Co Inc | Moduladores de los receptores de estrogeno |
-
2005
- 2005-12-05 US US11/792,729 patent/US7511152B2/en active Active
- 2005-12-05 RU RU2007125655/04A patent/RU2394820C2/ru not_active IP Right Cessation
- 2005-12-05 WO PCT/US2005/043859 patent/WO2006062876A2/en active Application Filing
- 2005-12-05 BR BRPI0518874-1A patent/BRPI0518874A2/pt not_active IP Right Cessation
- 2005-12-05 NZ NZ555316A patent/NZ555316A/en not_active IP Right Cessation
- 2005-12-05 KR KR1020077012865A patent/KR20070085874A/ko not_active Application Discontinuation
- 2005-12-05 MX MX2007006878A patent/MX2007006878A/es active IP Right Grant
- 2005-12-05 CN CN2005800422962A patent/CN101087606B/zh not_active Expired - Fee Related
- 2005-12-05 AU AU2005314230A patent/AU2005314230B2/en not_active Ceased
- 2005-12-05 CA CA2590860A patent/CA2590860C/en not_active Expired - Fee Related
- 2005-12-05 EP EP05852923.1A patent/EP1827421B1/en active Active
- 2005-12-05 JP JP2007545542A patent/JP2008523065A/ja not_active Withdrawn
-
2007
- 2007-05-22 ZA ZA200704223A patent/ZA200704223B/xx unknown
- 2007-05-29 IL IL183543A patent/IL183543A/en not_active IP Right Cessation
- 2007-07-06 NO NO20073511A patent/NO20073511L/no not_active Application Discontinuation
-
2011
- 2011-10-28 JP JP2011237399A patent/JP2012092103A/ja active Pending
Non-Patent Citations (1)
Title |
---|
李小红等.选择性雌激素受体调节剂的作用机制研究近况.天津药学.2003,15(6),49-51. * |
Also Published As
Publication number | Publication date |
---|---|
IL183543A (en) | 2015-03-31 |
CA2590860A1 (en) | 2006-06-15 |
JP2012092103A (ja) | 2012-05-17 |
CN101087606A (zh) | 2007-12-12 |
ZA200704223B (en) | 2008-08-27 |
WO2006062876A3 (en) | 2006-09-14 |
AU2005314230B2 (en) | 2011-05-19 |
RU2394820C2 (ru) | 2010-07-20 |
RU2007125655A (ru) | 2009-01-20 |
NZ555316A (en) | 2009-08-28 |
NO20073511L (no) | 2007-09-07 |
WO2006062876A2 (en) | 2006-06-15 |
BRPI0518874A2 (pt) | 2008-12-16 |
AU2005314230A1 (en) | 2006-06-15 |
MX2007006878A (es) | 2007-06-22 |
EP1827421B1 (en) | 2017-09-27 |
KR20070085874A (ko) | 2007-08-27 |
CA2590860C (en) | 2011-05-03 |
IL183543A0 (en) | 2007-09-20 |
EP1827421A4 (en) | 2011-03-30 |
EP1827421A2 (en) | 2007-09-05 |
US7511152B2 (en) | 2009-03-31 |
US20070265318A1 (en) | 2007-11-15 |
JP2008523065A (ja) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101087606B (zh) | 雌激素受体调节剂 | |
CN101068764B (zh) | 雌激素受体调节剂 | |
CN1976944A (zh) | 雌激素受体调节剂 | |
US20040210080A1 (en) | Selective estrogen receptor modulators | |
JP2003531855A (ja) | エストロゲンレセプターモデュレーター | |
CN1968960A (zh) | 雌激素受体调节剂 | |
JP2003528057A (ja) | 抗エストロゲン作用を有する4−フルオルアルキル−2h−ベンゾピラン | |
WO2004073612A2 (en) | Estrogen receptor modulators | |
EP1943224B1 (en) | Estrogen receptor modulators | |
CN1886418A (zh) | 雌激素受体调节剂 | |
WO2004073610A2 (en) | Estrogen receptor modulators | |
CN105801564B (zh) | 哌嗪酮类化合物及其应用 | |
WO2008057309A2 (en) | Estrogen receptor modulators | |
US7709508B2 (en) | Estrogen receptor modulators | |
JP2006508927A (ja) | エストロゲン受容体修飾因子 | |
AU2002326590A1 (en) | Selective estrogen receptor modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SCHERING CORP (US) Free format text: FORMER OWNER: MSD CORP. Effective date: 20121031 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: MSD CORP. Free format text: FORMER NAME: SCHERING CORP (US) |
|
CP01 | Change in the name or title of a patent holder |
Address after: New jersey, USA Patentee after: MERCK SHARP & DOHME Corp. Address before: New jersey, USA Patentee before: SCHERING Corp. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20121031 Address after: New jersey, USA Patentee after: SCHERING Corp. Address before: New jersey, USA Patentee before: MERCK SHARP & DOHME Corp. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101229 Termination date: 20171205 |
|
CF01 | Termination of patent right due to non-payment of annual fee |